A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

To join this study, you must be an adult aged 18 or over and have a confirmed diagnosis of small cell lung cancer that has spread (extensive-stage) and has come back after your first platinum-based chemotherapy. You must have received that first treatment for at least two cycles, and your cancer must have progressed more than 30 days afterwards. You'll also need to have at least one measurable tumour for doctors to track, and your general health and organ function must be good enough to take part.

There are also reasons why you might not be able to join. For example, if you had a different type of small cell lung cancer at diagnosis, or if your cancer has spread to your brain causing symptoms. You also can't have certain other serious health issues, like uncontrolled heart problems or active infections, or have received specific types of previous cancer treatments that target B7-H3 or use a similar drug type to Ris-Rez.

If you decide to participate in this study, you will be randomly assigned to one of two treatment groups: either receiving the new medicine, Ris-Rez, or the standard treatment, topotecan. Both treatments will involve regular visits to the clinic for your medicine, close monitoring by the study team, and various tests like blood tests and scans to check your health and how the treatment is working. The specific schedule of visits and tests will be explained in detail by the study team.

The total duration of your participation will depend on how you respond to the treatment and your overall health. You will continue to receive treatment for as long as it is helping you and you are tolerating it well. Even after you stop treatment, there will be follow-up appointments to track your health and long-term outcomes for a certain period. The study team will provide all the necessary information about what to expect, including the frequency of visits and how long you might be involved.